Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Collaboration › Details

Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform

 

Period Period 2019-11-07
Organisation Partner, 1st Thermo Fisher Scientific Inc. (NYSE: TMO)
  Group Thermo Fisher (Group)
Products Product Q Exactive™ GC Quadrupole-Orbitrap system
  Product 2 Breath Biopsy® platform
Person Person Bern, Morten (Thermo Fisher 201510 Senior Director + General Manager GC-MS)
     

Owlstone Medical Ltd.. (11/7/19). "Press Release: Owlstone Medical Enters Partnership with Thermo Fisher Scientific to Advance Early Disease Detection Using Non-invasive Breath Biopsy". Cambridge.

Thermo Fisher Scientific Orbitrap GC-MS technology to be integrated into Breath Biopsy to support identification of novel biomarkers for early disease detection


Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.

Under the agreement, both parties will work to integrate the Thermo Scientific™ Q Exactive™ GC Hybrid Quadrupole-Orbitrap™ Mass Spectrometer into Owlstone Medical’s Breath Biopsy platform. An initial project will seek to qualify the mass analyzer for the detection of new biomarkers via a validated discovery and routine analysis project. Upon successful completion, the technology will then become a standard part of Owlstone Medical’s biomarker discovery process, whereby metabolomic studies are conducted on breath samples for internal programs, or on behalf of pharmaceutical or academic clients, to discover novel biomarkers that could translate into research and clinical tests. The work will take place at Owlstone Medical’s Cambridge, UK, Breath Biopsy laboratory.

“There is clearly a growing need for non-invasive diagnostic solutions to support the early detection of disease.” said Morten Bern, senior director marketing, chromatography and mass spectrometry, Thermo Fisher Scientific. “The integration of our Orbitrap GC-MS technology with Owlstone Medical’s Breath Biopsy platform provides a unique basis to improve patient outcomes through the discovery of breath biomarkers and their incorporation into clinical practice.”

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “The GC Orbitrap platform’s ability to detect a wide range of chemicals during both targeted and untargeted analyses without losing selectivity or sensitivity, promises to be of substantial benefit to our Breath Biopsy platform. With a large and rapidly expanding installed base of GC Orbitrap systems, our partnership with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of Breath Biopsy can be broadly realized.”

Further to the scientific and technical expertise, this collaboration will be supported by a joint marketing and customer support effort to ensure the global reach of the Breath Biopsy platform.


ENDS


Notes to Editors:

For more information please contact:

Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0) 7771-730919

Or

Frazer Hall, Citigate Dewe Rogerson
Frazer.Hall@citigatedewerogerson.com
+44 (0) 20 7282 2822


What is Breath Biopsy®?

Breath Biopsy represents an entirely new way to measure the chemical makeup of breath by measuring volatile organic compounds (VOCs), which are gaseous molecules that can be sampled quickly and non-invasively from breath and enabling whole-body sampling. These compounds are produced as the end product of metabolic processes within the body, meaning underlying changes in metabolic activity can produce particular patterns of VOCs characteristic of specific diseases.

VOCs originating from all parts of the body are captured in breath, making Breath Biopsy applicable to a wide range of diseases including cancer, inflammatory disease, infectious disease, metabolic disease, cardiovascular disease and respiratory disease. The nature of Breath Biopsy, and VOC biomarkers, make them perfectly suited to addressing two of the major challenges of healthcare today: early detection and precision medicine.

Breath collection is carried out using Owlstone Medical’s ReCIVA® Breath Sampler, which ensures reliable, reproducible collection of VOCs. Subjects breathe a controlled supply of air, and samples of their exhaled breath are captured and stabilized on Breath Biopsy Cartridges, which can then be shipped for analysis with Owlstone Medical’s Breath Biopsy analytical platform, using mass spectrometry or FAIMS to determine their VOC profile. Advanced data analytic techniques can then be applied in order to pinpoint the VOCs of interest.

   
Record changed: 2019-11-22

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Owlstone (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top